Clearmind Medicine begins clinical trial for CMND-100, a psychedelic treatment for alcohol use disorder

From Nasdaq: 2025-03-18 19:50:12

Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a psychedelic-derived treatment for Alcohol Use Disorder. The trial will evaluate safety, tolerability, and pharmacokinetics, with sites in Israel and the U.S. CEO Adi Zuloff-Shani highlighted the importance of this milestone, given the global health crisis of AUD. WHO estimates 400 million people worldwide have alcohol use disorders, with 2.6 million deaths annually. In the U.S., 15.1% of adults aged 18-25 met AUD criteria in 2023. On Tuesday, CMND closed at $1.20 on the Nasdaq Capital Market.



Read more at Nasdaq: Clearmind Medicine Advances CMND-100 To Clinical Trials For Alcohol Use Disorder